VetSRev
Database of veterinary systematic reviews
Database of veterinary systematic reviews
Sci Rep (2018) 8: 4181
DOI: 10.1038/s41598-018-22316-7
Antisense oligonucleotide (AON)-based therapies hold promise for a range of neurodegenerative and neuromuscular diseases and have shown benefit in animal models and patients. Success in the clinic is nevertheless still limited, due to unfavourable biodistribution and poor cellular uptake of AONs. Extensive research is currently being conducted into the formulation of AONs to improve delivery, but thus far there is no consensus on which of those strategies will be the most effective. This systematic review was designed to answer in an unbiased manner which delivery strategies most strongly enhance the efficacy of AONs in animal models of heritable neurodegenerative and neuromuscular diseases. In total, 95 primary studies met the predefined inclusion criteria. Study characteristics and data on biodistribution and toxicity were extracted and reporting quality and risk of bias were assessed. Twenty studies were eligible for meta-analysis. We found that even though the use of delivery systems provides an advantage over naked AONs, it is not yet possible to select the most promising strategies. Importantly, standardisation of experimental procedures is warranted in order to reach conclusions about the most efficient delivery strategies. Our best practice guidelines for future experiments serve as a step in that direction.
van der Bent, M. L., Paulino da Silva Filho, O., van Luijk, J., Brock, R., & Wansink, D. G. (2018). Assisted delivery of antisense therapeutics in animal models of heritable neurodegenerative and neuromuscular disorders: a systematic review and meta-analysis. Sci Rep, 8(1), 4181. https://doi.org/10.1038/s41598-018-22316-7 Animals, *Disease Models, Animal, *Heredodegenerative Disorders, Nervous System/genetics/therapy, *Neuromuscular Diseases/genetics/therapy, *Oligonucleotides, Antisense/pharmacokinetics/therapeutic use, Drug Delivery Systems/*methods